Operation Infinite Justice – Lifestyle
Author:
Medicenna Therapeutics Corp.
Medicenna Presents Positive Data Demonstrating Superior Safety and Efficacy Potential of its First-in-Class anti-PD-1 x IL-2 Bifunctional Superkine MDNA113 at AACR 2026
April 21, 2026
Medicenna to Present at the 2026 Bloom Burton & Co. Healthcare Investor Conference
April 14, 2026
Medicenna Therapeutics Appoints Dr. Nageatte Ibrahim as Chief Medical Officer
April 9, 2026
Medicenna to Present Preclinical Data from its First-in-Class Tumor Anchored and Conditionally Activated Anti-PD-1-IL-2 Bifunctional Superkine at the AACR Annual Meeting 2026
March 18, 2026